Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Inflamm Bowel Dis. 2010 Dec;16(12):2168-72. doi: 10.1002/ibd.21305.
Patients with inflammatory bowel disease are commonly treated with immunomodulators and biologic therapy. These treatments can be very effective, but are associated with risks of adverse events that need to be discussed with patients. Effectively communicating risks of therapy can be challenging based on time constraints, misinformation available on the Internet and from others, and the lack of tools to efficiently share accurate data with patients and their families. Providers need to acknowledge the emotional aspect involved in the perception of risk, and be aware of mistakes that can easily be made in communicating with patients. Tools are available to make medical data easier to understand, and these techniques have been adapted for patients with inflammatory bowel disease. By more clearly communicating with patients, we can ensure that they are making informed medical decisions that fit with their personal preferences for treatment.
患有炎症性肠病的患者通常会接受免疫调节剂和生物疗法的治疗。这些治疗方法可能非常有效，但也存在不良事件的风险，需要与患者讨论。由于时间限制、互联网和他人提供的错误信息以及缺乏有效工具与患者及其家属共享准确数据，因此有效地沟通治疗风险具有挑战性。提供者需要承认在感知风险中涉及的情感方面，并意识到在与患者沟通时容易犯的错误。有一些工具可以使医疗数据更容易理解，并且这些技术已经适用于炎症性肠病患者。通过更清楚地与患者沟通，我们可以确保他们做出符合个人治疗偏好的明智医疗决策。
